Dose modifications based on toxicities 1

  • Monitor blood counts frequently through resolution of cytopenias
  • Management of some adverse reactions may require dose interruptions or permanent discontinuation of VENCLEXTA

Dose modifications for use with CYP3A and P-gp inhibitors 1

  • The following table describes VENCLEXTA dosage modification based on concomitant use with a strong or moderate CYP3A inhibitor or P-gp inhibitor at initiation, during, or after the ramp-up phase
  • Resume the VENCLEXTA dosage that was used prior to initiating the CYP3A inhibitor or P-gp inhibitor 2 to 3 days after discontinuation of the inhibitor

Dose modifications for patients with severe hepatic impairment

  • Reduce the VENCLEXTA once-daily dose by 50% for patients with severe hepatic impairment (Child-Pugh C); monitor these patients more closely for signs of toxicity

AML=acute myeloid leukemia.
*Adverse reactions were graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.